NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

CDTX

Cidara Therapeutics Inc

Jul 03 • 04:00PM ET

48.78

Dollar change +0.91
Percentage change 1.90	%

Healthcare • Biotechnology • USA • NASD

Peers: JNJ GILD REGN PFE AMGN MRNA VRTX BMY SNY BIIB

| Held by: IWM VTI IWN DWAS IWC VXF VFMO AVSC PRFZ RSSL

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-29.07	Insider Own	40.83%	Shs Outstand	22.12M	Perf Week	1.56%
Market Cap	1.08B	Forward P/E	-	EPS next Y	-7.67	Insider Trans	33.63%	Shs Float	13.09M	Perf Month	109.36%
Enterprise Value	907.07M	PEG	-	EPS next Q	-1.96	Inst Own	47.21%	Short Float	4.95%	Perf Quarter	165.54%
Income	-181.18M	P/S	3596.30	EPS this Y	71.38%	Inst Trans	83.44%	Short Ratio	1.24	Perf Half Y	93.19%
Sales	0.30M	P/B	4.20	EPS next Y	-0.19%	ROA	-151.85%	Short Interest	0.65M	Perf YTD	81.47%
Book/sh	11.60	P/C	6.18	EPS next 5Y	36.33%	ROE	-299.58%	52W High	56.83 -14.16%	Perf Year	305.15%
Cash/sh	7.89	P/FCF	-	EPS past 3/5Y	-17.79% 1.30%	ROIC	-126.77%	52W Low	10.14 381.07%	Perf 3Y	360.19%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-70.48% -42.85%	Gross Margin	25.17%	Volatility	8.77% 9.71%	Perf 5Y	-38.56%
Dividend TTM	-	EV/Sales	3023.57	EPS Y/Y TTM	-260.33%	Oper. Margin	-37568.21%	ATR (14)	4.16	Perf 10Y	-83.05%
Dividend Ex-Date	-	Quick Ratio	3.87	Sales Y/Y TTM	-99.35%	Profit Margin	-59994.04%	RSI (14)	77.98	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.87	EPS Q/Q	27.22%	SMA20	40.64%	Beta	1.17	Target Price	59.00
Payout	-	Debt/Eq	0.02	Sales Q/Q	-100.00%	SMA50	79.64%	Rel Volume	0.79	Prev Close	47.87
Employees	38	LT Debt/Eq	0.01	Earnings	May 08 AMC	SMA200	136.16%	Avg Volume	520.89K	Price	48.78
IPO	Apr 15, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	53.15% -	Trades		Volume	412,729	Change	1.90%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-18-25	Resumed	H.C. Wainwright	Buy	$41
Mar-12-25	Initiated	Citizens JMP	Mkt Outperform	$46
Jan-27-25	Resumed	Cantor Fitzgerald	Overweight
Dec-13-24	Initiated	RBC Capital Mkts	Outperform	$34
Nov-08-24	Initiated	Guggenheim	Buy	$33
Aug-14-24	Upgrade	H.C. Wainwright	Neutral → Buy	$24
Dec-03-21	Resumed	H.C. Wainwright	Buy	$6
Sep-22-21	Upgrade	WBB Securities	Buy → Strong Buy	$6.25
Mar-04-21	Initiated	Aegis Capital	Buy	$9
Sep-04-19	Upgrade	Wedbush	Neutral → Outperform	$2 → $4
Jul-26-18	Initiated	Citigroup	Buy	$8
Apr-21-17	Initiated	Raymond James	Strong Buy
Apr-17-17	Reiterated	H.C. Wainwright	Buy	$18 → $14
Apr-12-17	Initiated	Ladenburg Thalmann	Buy	$11.25
Apr-11-17	Resumed	Wedbush	Outperform	$13
Feb-22-17	Upgrade	WBB Securities	Sell → Hold	$7.25
Feb-22-17	Reiterated	H.C. Wainwright	Buy	$25 → $18
Dec-21-16	Resumed	Leerink Partners	Outperform
Dec-19-16	Initiated	H.C. Wainwright	Buy	$25
Sep-23-16	Downgrade	WBB Securities	Hold → Sell	$10.50

Show Previous Ratings

Jul-03-25 04:06PM	Warner Bros., Cidara, LENZ Therapeutics, and More Stocks See Action From Activist Investors (Barrons.com)
Jul-01-25 04:59PM	Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Jun-30-25 02:21PM	Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains (MarketBeat)
08:00AM	Cidara Therapeutics Announces Inclusion in the Russell 2000 and Russell 3000 Indexes (GlobeNewswire)
Jun-26-25 05:15PM	Cidara Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
08:00PM	Loading…
Jun-24-25 08:00PM	Cidara Announces Pricing of Upsized Public Offering of Common Stock (GlobeNewswire) +5.32%
Jun-23-25 04:25PM	Cidara Therapeutics Doubles As A Universal Flu Shot Becomes A Closer Reality (Investor's Business Daily) +113.84%
04:15PM	Cidara Announces Proposed Public Offering of Common Stock (GlobeNewswire)
11:20AM	Cidara Launches 93% As A Universal Flu Shot Becomes A Closer Reality (Investor's Business Daily)
08:27AM	Cidara stock soars as antiviral drug succeeds in flu study (BioPharma Dive)
07:00AM	Cidara Therapeutics Announces Positive Topline Results from its Phase 2b NAVIGATE Trial Evaluating CD388, a Non-Vaccine Preventative of Seasonal Influenza (GlobeNewswire)
May-15-25 08:00AM	Cidara Therapeutics to Host Virtual R&D Day to Discuss CD388 as a Potential Universal, Once-Per-Flu Season Preventative of Seasonal and Pandemic Influenza on May 22, 2025 (GlobeNewswire) +8.99%
May-13-25 08:00AM	Cidara Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
May-09-25 03:48AM	Cidara Therapeutics Inc (CDTX) Q1 2025 Earnings Call Highlights: Promising Advances in ... (GuruFocus.com)
May-08-25 04:38PM	Cidara Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:15PM	Loading…
04:15PM	Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-05-25 05:00AM	Cidara Therapeutics: Strong Buy On Imminent Data Readout For Lead Flu Candidate (Seeking Alpha)
May-01-25 08:00AM	Cidara Therapeutics Announces Promotion of Nicole Davarpanah to Chief Medical Officer and Corrina Pavetto to SVP, Clinical Development (GlobeNewswire)
Apr-30-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Cidara Therapeutics (CDTX) is a Great Choice (Zacks)
08:00AM	Cidara Therapeutics to Participate in The Citizens Life Sciences Conference (GlobeNewswire)
Apr-24-25 08:00AM	Cidara Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 8, 2025 (GlobeNewswire)
Apr-16-25 08:00AM	Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors (GlobeNewswire)
Apr-01-25 04:56PM	Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) -12.16%
04:05PM	Cidara Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-21-25 09:55AM	Wall Street Analysts Predict a 64.5% Upside in Cidara Therapeutics (CDTX): Here's What You Should Know (Zacks)
Mar-19-25 08:12AM	Cidara Therapeutics to present on CD388 at ICAR 2025 (TipRanks)
08:00AM	Cidara Therapeutics to Participate in World Health Organization Meeting on H5N1 Influenza Preparedness and Response (GlobeNewswire)
Mar-18-25 08:00AM	Cidara Therapeutics Announces Two Presentations on CD388 in Influenza at International Conference on Antiviral Research (ICAR) 2025 (GlobeNewswire)
Mar-17-25 06:00AM	Cidara Therapeutics Announces Publication of CD388 Preclinical Data in Nature Microbiology (GlobeNewswire)
Mar-06-25 05:03PM	Cidara Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:35PM	Loading…
04:35PM	Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-18-25 04:15PM	Cidara Therapeutics Announces Appointment of Frank Karbe as Chief Financial Officer (GlobeNewswire)
Jan-30-25 04:05PM	Cidara Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference (GlobeNewswire)
Jan-13-25 03:37PM	Here's Why Cidara Therapeutics, Inc. (CDTX) Is Skyrocketing (Insider Monkey) -11.71%
Dec-05-24 11:07AM	Cidara achieves full enrolment in influenza prevention trial (Clinical Trials Arena)
Dec-04-24 08:00AM	Cidara Therapeutics Completes Enrollment of Phase 2b NAVIGATE Trial Evaluating CD388 for Prevention of Seasonal Influenza (GlobeNewswire) +12.65%
Dec-03-24 09:55AM	Cidara Therapeutics (CDTX) Just Flashed Golden Cross Signal: Do You Buy? (Zacks) -5.60%
Nov-21-24 08:30AM	Cidara Therapeutics Announces $105 Million Private Placement (GlobeNewswire) +15.41%
Nov-19-24 08:00AM	Cidara Therapeutics to Participate in Evercore 7th Annual HealthCONx Conference (GlobeNewswire)
Nov-07-24 05:09PM	Cidara Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-31-24 08:00AM	Cidara Therapeutics to Participate in Two Upcoming November Investor Conferences (GlobeNewswire)
Oct-16-24 08:00AM	Cidara Therapeutics Announces Two Presentations on Drug-Fc Conjugate, CD388, at IDWeek 2024 (GlobeNewswire) +5.60%
Oct-04-24 04:30PM	Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Sep-25-24 08:00AM	Cidara Therapeutics Announces Two Presentations on Innovative Drug-Fc Conjugate, CD388, at the 2024 OPTIONS XII for the Control of Influenza Conference (GlobeNewswire)
Sep-23-24 08:00AM	Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza (GlobeNewswire)
Sep-19-24 08:00AM	Cidara Therapeutics Strengthens its Scientific Advisory Board with Infectious Disease Experts (GlobeNewswire)
Sep-13-24 10:13AM	Cidara axes 30% of staff to focus on flu prevention drug (Pharmaceutical Technology) +5.20%
07:53AM	Cidara buys back rights to flu therapy from J&J for $85m (Pharmaceutical Technology)
Sep-12-24 04:05PM	Cidara Therapeutics Restructures Workforce to Focus on Planned Clinical Development of CD388 (GlobeNewswire)
Sep-05-24 08:00AM	Cidara to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-19-24 05:12PM	Cidara Therapeutics Announces Appointment of Jim Beitel as Chief Business Officer (GlobeNewswire)
Aug-13-24 05:25PM	Cidara Therapeutics: Q2 Earnings Snapshot (Associated Press Finance) +5.84%
04:29PM	Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-03-24 01:05PM	Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-30-24 08:00AM	Cidara Therapeutics to Present Preclinical Data on CD388 at ASM Microbe 2024 Conference (GlobeNewswire) +5.08%
May-15-24 10:54PM	CDTX Stock Earnings: Cidara Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) -5.59%
04:30PM	Cidara Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:20PM	Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
04:01PM	Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing Rules (GlobeNewswire)
Apr-26-24 08:00AM	Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024 (GlobeNewswire)
Apr-25-24 07:52AM	Top Premarket Gainers (MT Newswires) +5.78%
Apr-24-24 04:05PM	Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million (GlobeNewswire) +19.90%
04:01PM	Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline (GlobeNewswire)
Apr-23-24 05:11AM	Cidara Therapeutics Q4 Loss Narrows as Sales Rise; Shares Surge Premarket (MT Newswires)
Apr-22-24 09:52PM	CDTX Stock Earnings: Cidara Therapeutics Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) -24.54%
05:10PM	Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
05:06PM	Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice (GlobeNewswire)
08:49AM	Cidara Therapeutics Announces Reverse Stock Split (GlobeNewswire)
Apr-05-24 03:00PM	Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024 (GlobeNewswire) +7.41%
Mar-06-24 08:00AM	Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association for Cancer Research (AACR) Annual Meeting 2024 (GlobeNewswire)
08:00AM	Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association dor Cancer Research (AACR) Annual Meeting 2024 (GlobeNewswire)
Feb-15-24 03:15AM	Steven Cohen's Point72 Adds Cidara Therapeutics to Its Portfolio (GuruFocus.com)
Feb-12-24 08:00AM	Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO (GlobeNewswire)
Jan-29-24 04:30PM	Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults (GlobeNewswire)
Dec-26-23 10:51AM	Cidara (CDTX) Up on EC Nod for Rezzayo in Invasive Candidiasis (Zacks) -5.49%
Dec-22-23 07:30AM	Cidara Therapeutics Announces European Approval of REZZAYO (rezafungin) for the Treatment of Invasive Candidiasis in Adults (GlobeNewswire) +11.13%
Dec-07-23 08:00AM	Cidara Therapeutics Presents New Promising Preclincal Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress (GlobeNewswire)
Dec-06-23 08:00AM	Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China (GlobeNewswire)
Nov-30-23 08:00AM	Cidara Therapeutics to Present New Preclinical Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress (GlobeNewswire)
Nov-20-23 08:00AM	Cidara Therapeutics Named as a San Diego Metro Area Top Workplace (GlobeNewswire)
Nov-03-23 12:00PM	Cidara Therapeutics Presents Preclinical Data on Novel Drug-Fc Conjugate CBO421 at SITC's 38 Annual Meeting (GlobeNewswire) -6.33%
Nov-02-23 07:33PM	Cidara Therapeutics Inc (CDTX) Reports Q3 2023 Financial Results (GuruFocus.com) +7.62%
04:32PM	Cidara Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-13-23 10:34AM	Cidara Therapeutics and Mundipharma receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults(1) (GlobeNewswire)
Oct-11-23 08:30AM	Cidara Therapeutics Presents New Preclinical and Clinical Data on Novel Drug-Fc Conjugate CD388 at IDWeek 2023 (GlobeNewswire)
Sep-29-23 04:51PM	Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-27-23 08:00AM	Cidara Therapeutics to Present New Data on Novel drug-Fc conjugate CD388 at IDWeek 2023 (GlobeNewswire)
Sep-14-23 01:17AM	Insider Sell: Chief Scientific Officer Leslie Tari Sells 18,469 Shares of Cidara Therapeutics Inc (GuruFocus.com)
Sep-07-23 08:00AM	Cidara Therapeutics to Host Virtual Research & Development Day on its Cloudbreak® Development Pipeline on September 21, 2023 (GlobeNewswire)
Sep-06-23 04:05PM	Cidara to Present at the 25th Annual H.C. Wainwright Global Investment Conference (GlobeNewswire) +26.07%
08:00AM	Cidara Therapeutics Announces Janssens Election to Proceed Under its License Agreement Relating to Novel Drug-Fc Conjugates Targeting Influenza (GlobeNewswire)
Aug-28-23 10:17PM	Want to Get Rich? 3 Game-Changing Penny Stocks to Buy Right Now (InvestorPlace) +7.01%
Aug-16-23 08:00AM	Cidara Therapeutics Announces Appointment of Nicole Davarpanah, M.D., J.D., as Senior Vice President of Translational Research & Development (GlobeNewswire)
Aug-09-23 06:04AM	Downgrade: Here's How Analysts See Cidara Therapeutics, Inc. (NASDAQ:CDTX) Performing In The Near Term (Simply Wall St.)
Aug-06-23 08:24AM	Cidara Therapeutics, Inc.'s (NASDAQ:CDTX) Shift From Loss To Profit (Simply Wall St.)
Aug-03-23 05:25PM	Cidara Therapeutics (CDTX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:21PM	Cidara Therapeutics: Q2 Earnings Snapshot (AP Finance)
04:08PM	Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire)

Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of therapeutics for patients facing serious diseases, specifically oncology and infectious diseases. Its product pipeline includes Rezafungin Acetate and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RA CAPITAL MANAGEMENT, L.P.	Director	Jun 26 '25	Buy	44.00	2,272,727	99,999,988	3,365,523	Jun 30 04:56 PM
Mineo Chrysa	Director	Jun 02 '25	Buy	21.71	2,270	49,281	2,270	Jun 04 04:23 PM
Mineo Chrysa	Director	Jun 03 '25	Buy	23.44	1,050	24,614	3,320	Jun 04 04:23 PM
Ward Shane	COO & CLO	Mar 11 '25	Sale	21.96	1,664	36,542	14,674	Mar 13 06:34 PM
Tari Leslie	CHIEF SCIENTIFIC OFFICER	Mar 11 '25	Sale	21.96	1,773	38,940	16,215	Mar 13 06:33 PM
Sandison Taylor	Chief Medical Officer	Sep 11 '24	Sale	11.64	924	10,752	23,067	Sep 13 06:27 PM
Tari Leslie	CHIEF SCIENTIFIC OFFICER	Sep 11 '24	Sale	11.64	909	10,580	17,788	Sep 13 06:26 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CDTX

Cidara Therapeutics Inc

Upgrade your FINVIZ experience